Amedisys Inc (NASDAQ:AMED) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Friday.
Other research analysts have also issued research reports about the company. Zacks Investment Research upgraded Amedisys from a “hold” rating to a “buy” rating and set a $59.00 target price for the company in a research report on Monday, April 17th. Royal Bank Of Canada restated a “hold” rating and set a $56.00 target price on shares of Amedisys in a research report on Monday, June 5th. Stephens boosted their target price on Amedisys from $50.00 to $54.00 and gave the company an “equal weight” rating in a research report on Thursday, May 4th. Benchmark Co. restated a “hold” rating and set a $57.00 target price (up previously from $50.00) on shares of Amedisys in a research report on Wednesday, May 3rd. Finally, Mizuho lowered Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 target price for the company. in a research report on Wednesday, July 26th. Six analysts have rated the stock with a hold rating and four have given a buy rating to the company. Amedisys currently has a consensus rating of “Hold” and an average price target of $56.50.
Shares of Amedisys (NASDAQ AMED) opened at 48.88 on Friday. Amedisys has a 1-year low of $34.58 and a 1-year high of $65.91. The stock has a 50 day moving average price of $56.08 and a 200-day moving average price of $54.19. The company has a market cap of $1.66 billion, a price-to-earnings ratio of 41.78 and a beta of 0.89.
Amedisys (NASDAQ:AMED) last announced its earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.12. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The business had revenue of $378.80 million during the quarter, compared to analyst estimates of $380.80 million. During the same quarter in the previous year, the business earned $0.42 earnings per share. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. Equities research analysts forecast that Amedisys will post $2.21 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This article was originally published by Transcript Daily and is the property of of Transcript Daily. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://transcriptdaily.com/2017/08/13/bidaskclub-upgrades-amedisys-inc-nasdaqamed-to-hold.html.
In other news, insider David B. Pearce sold 1,000 shares of Amedisys stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $50.00, for a total transaction of $50,000.00. Following the completion of the sale, the insider now owns 10,488 shares of the company’s stock, valued at $524,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bruce D. Perkins purchased 500 shares of the firm’s stock in a transaction dated Thursday, May 25th. The shares were bought at an average cost of $59.69 per share, with a total value of $29,845.00. Following the purchase, the director now directly owns 13,331 shares of the company’s stock, valued at approximately $795,727.39. The disclosure for this purchase can be found here. Insiders own 2.80% of the company’s stock.
Several hedge funds have recently bought and sold shares of AMED. Norges Bank bought a new stake in Amedisys during the fourth quarter valued at $13,483,000. Bank of Montreal Can increased its stake in Amedisys by 8,881.4% in the first quarter. Bank of Montreal Can now owns 34,848 shares of the health services provider’s stock valued at $1,780,000 after buying an additional 34,460 shares in the last quarter. Louisiana State Employees Retirement System increased its stake in Amedisys by 1.8% in the first quarter. Louisiana State Employees Retirement System now owns 11,400 shares of the health services provider’s stock valued at $582,000 after buying an additional 200 shares in the last quarter. State of Alaska Department of Revenue increased its stake in Amedisys by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 3,080 shares of the health services provider’s stock valued at $157,000 after buying an additional 70 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in Amedisys by 77.7% in the first quarter. Russell Investments Group Ltd. now owns 36,295 shares of the health services provider’s stock valued at $1,854,000 after buying an additional 15,875 shares in the last quarter. 99.80% of the stock is owned by hedge funds and other institutional investors.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.